Eton Pharmaceuticals (NASDAQ:ETON) Sees Large Volume Increase

Eton Pharmaceuticals Inc (NASDAQ:ETON) saw unusually-strong trading volume on Tuesday . Approximately 2,215,807 shares traded hands during trading, an increase of 3,203% from the previous session’s volume of 67,076 shares.The stock last traded at $6.43 and had previously closed at $5.83.

Several analysts have issued reports on ETON shares. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Eton Pharmaceuticals in a research report on Monday, August 5th. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a report on Friday, September 20th. They set a “buy” rating and a $13.50 target price for the company. Lake Street Capital assumed coverage on shares of Eton Pharmaceuticals in a report on Monday, August 5th. They set a “buy” rating for the company. Zacks Investment Research lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Finally, ValuEngine upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $12.83.

The company has a quick ratio of 11.48, a current ratio of 11.48 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $6.14 and its two-hundred day moving average price is $6.96. The company has a market capitalization of $107.64 million and a PE ratio of -1.11.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.12. On average, equities research analysts forecast that Eton Pharmaceuticals Inc will post -1.11 EPS for the current year.

In other news, CEO Sean Brynjelsen bought 5,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was bought at an average cost of $6.15 per share, for a total transaction of $30,750.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 13.46% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ETON. BlackRock Inc. raised its stake in Eton Pharmaceuticals by 181.2% in the second quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock worth $206,000 after buying an additional 16,813 shares in the last quarter. Vanguard Group Inc. raised its stake in Eton Pharmaceuticals by 6.7% in the second quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock worth $227,000 after buying an additional 1,800 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Eton Pharmaceuticals by 122.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after buying an additional 1,728 shares in the last quarter. 9.95% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile (NASDAQ:ETON)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.

Read More: Why is the conference call important?

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit